Skip to main content
SpringerLink
Log in

Le mésothéliome : maladie orpheline ?

Mesothelioma: an orphan disease?

  • Mise Au Point / Update
  • Published:
Oncologie

Résumé

Le mésothéliome pleural malin (MPM) est une maladie néoplasique rare, avec environ 1 000 nouveaux cas chaque année en France. Est-ce pour autant une maladie orpheline ? C’est-à-dire une maladie rare pour laquelle aucun traitement efficace n’est disponible ? L’objectif de cet article est de répondre à cette question, à travers une mise au point sur la prise en charge thérapeutique du MPM en 2016.

Abstract

Malignant pleural mesothelioma (MPM) is a rare neoplastic disease, with approximately 1,000 new cases each year in France. Is it an orphan disease? Namely, a rare disease for which no effective treatment is available. The objective of this article is to answer this question through a focus on the therapeutic management of MPM in 2016.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Références

  1. Robinson BM (2012) Malignant pleural mesothelioma: an epidemiological perspective. Ann Cardiothorac Surg 1:491–6

    PubMed  PubMed Central  Google Scholar 

  2. Greillier L, Astoul P (2008) Mesothelioma and asbestos related pleural diseases. Respiration 76:1–15

    Article  CAS  PubMed  Google Scholar 

  3. Marinaccio A, Binazzi A, Cauzillo G, et al (2007) Analysis of latency time and its determinants in asbestos related malignant mesothelioma cases of the Italian register. Eur J Cancer 43:2722–8

    Article  CAS  PubMed  Google Scholar 

  4. Hodgson JT, Mc Elvenny DM, Darnton AJ, et al (2005) The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050. Br J Cancer 92:587–93

    CAS  PubMed  PubMed Central  Google Scholar 

  5. Peto J, Decarli A, La Vecchia C, et al (1999) The European mesothelioma epidemic. Br J Cancer 79:666–72

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Le Stang N, Belot A, Gilg Soit Ilg A, et al (2010) Evolution of pleural cancers and malignant pleural mesothelioma incidence in France between 1980 and 2005. Int J Cancer 126:232–8

    Article  PubMed  Google Scholar 

  7. Price B, Ware A (2009) Time trend of mesothelioma incidence in the United States and projection of future cases: an update based on SEER data for 1973 through 2005. Crit Rev Toxicol 39:576–88

    Article  PubMed  Google Scholar 

  8. Scherpereel A, Astoul P, Baas P, et al (2010) Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Respir J 35:479–95

    Article  CAS  PubMed  Google Scholar 

  9. Delourme J, Dhalluin X, Cortot AB, et al (2013) Malignant pleural mesothelioma: diagnosis and treatment. Rev Pneumol Clin 69:26–35

    Article  CAS  PubMed  Google Scholar 

  10. Rintoul RC, Ritchie AJ, Edwards JG, et al (2014) Efficacy and cost of video-assisted thoracoscopic partial pleurectomy versus talc pleurodesis in patients with malignant pleural mesothelioma (MesoVATS): an open-label, randomised, controlled trial. Lancet 384:1118–27

    Article  PubMed  Google Scholar 

  11. Rice D (2011) Surgical therapy of mesothelioma. Recent Results Cancer Res 189:97–125

    Article  CAS  PubMed  Google Scholar 

  12. Krug LM, Pass HI, Rusch VW, et al (2009) Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol 27:3007–13

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Van Schil PE, Baas P, Gaafar R, et al (2010) Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial. Eur Respir J 36:1362–9

    Article  PubMed  Google Scholar 

  14. Weder W, Stahel RA, Bernhard J, et al (2007) Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann Oncol 18:1196–202

    Article  CAS  PubMed  Google Scholar 

  15. Treasure T, Lang-Lazdunski L, Waller D, et al (2011) Extrapleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the mesothelioma and radical surgery (MARS) randomised feasibility study. Lancet Oncol 12:763–72

    Article  PubMed  PubMed Central  Google Scholar 

  16. Cao C, Tian D, Park J, et al (2014) A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma. Lung Cancer 83:240–5

    Article  PubMed  Google Scholar 

  17. Boutin C, Rey F, Viallat JR (1995) Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy. Chest 108:754–8

    CAS  PubMed  Google Scholar 

  18. Scherpereel A (2006) The experts’ conference of the Société de pneumologie de langue française (SPLF) on malignant pleural mesothelioma (MPM): useful and necessary recommendations. Rev Mal Respir 23:11S5–S6

    Google Scholar 

  19. Bydder S, Phillips M, Joseph DJ, et al (2004) A randomized trial of single-dose radiotherapy to prevent procedure tract metastasis by malignant mesothelioma. Br J Cancer 91:9–10

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. O’Rourke N, Garcia JC, Paul J, et al (2007) A randomised controlled trial of intervention site radiotherapy in malignant pleural mesothelioma. Radiother Oncol 84:18–22

    Article  PubMed  Google Scholar 

  21. Rusch VW, Rosenzweig K, Venkatraman E, et al (2001) A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 122:788–95

    Article  CAS  PubMed  Google Scholar 

  22. Stahel RA, Riesterer O, Xyrafas A, et al (2015) Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial. Lancet Oncol 16:1651–8

    Article  PubMed  Google Scholar 

  23. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21:2636–44

    Article  CAS  PubMed  Google Scholar 

  24. van Meerbeeck JP, Gaafar R, Manegold C, et al (2005) Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 23:6881–9

    Article  PubMed  Google Scholar 

  25. Greillier L, Marco S, Barlesi F (2011) Targeted therapies in malignant pleural mesothelioma: a review of clinical studies. Anticancer Drugs 22:199–205

    Article  CAS  PubMed  Google Scholar 

  26. Krug LM, Kindler HL, Calvert H, et al (2015) Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Oncol 16:447–56

    Article  CAS  PubMed  Google Scholar 

  27. Edwards JG, Cox G, Andi A, et al (2001) Angiogenesis is an independent prognostic factor in malignant mesothelioma. Br J Cancer 85:863–8

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Zalcman G, Mazieres J, Margery J, et al (2016) Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet 387:1405–14

    Article  CAS  PubMed  Google Scholar 

  29. Calabrò L, Morra A, Fonsatti E, et al (2013) Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial. Lancet Oncol 14:1104–11

    Article  PubMed  Google Scholar 

  30. Calabrò L, Morra A, Fonsatti E, et al (2015) Efficacy and safety of an intensified schedule of tremelimumab for chemotherapyresistant malignant mesothelioma: an open-label, single-arm, phase 2 study. Lancet Respir Med 3:301–9

    Article  PubMed  Google Scholar 

  31. Kindler HL, Scherpereel A, Calabrò L, et al (2016) Tremelimumab as second-or third-line treatment of unresectable malignant mesothelioma (MM): results from the global, double-blind, placebo-controlled DETERMINE study. Annual Meeting of the American Society of Clinical Oncology: abstract 8502

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service d’oncologie multidisciplinaire et innovations thérapeutiques, Aix-Marseille Université, Assistance Publique–Hôpitaux de Marseille, Hôpital Nord, chemin des Bourrely, F-13915, Marseille cedex 20, France

    L. Greillier

  2. INSERM UMR_S 911, Faculté de médecine, Aix-Marseille Université, Marseille, France

    L. Greillier

Authors
  1. L. Greillier
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to L. Greillier.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Greillier, L. Le mésothéliome : maladie orpheline ?. Oncologie 18, 397–400 (2016). https://doi.org/10.1007/s10269-016-2642-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10269-016-2642-4

Mots clés

Keywords

Search

Navigation